Nanocrystal technology, drug delivery and clinical applications

By J. Junghanns, R. Müller. International Journal of Nanomedicine, 2008

972 citations recorded by the source corpus.

Nanotechnology will affect our lives tremendously over the next decade in very different fields, including medicine and pharmacy. Transfer of materials into the nanodimension changes their physical properties which were used in pharmaceutics to develop a new innovative formulation principle for poorly soluble drugs: the drug nanocrystals. The drug nanocrystals do not belong to the future; the first products are already on the market. The industrially relevant production technologies, pearl milling and high pressure homogenization, are reviewed. The physics behind the drug nanocrystals and changes of their physical properties are discussed. The marketed products are presented and the special physical effects of nanocrystals explained which are utilized in each market product. Examples of products in the development pipelines (clinical phases) are presented and the benefits for in vivo administration of drug nanocrystals are summarized in an overview.

Subfields: Biomaterials, Pharmaceutical Science

View Paper: https://www.semanticscholar.org/paper/24738d381a6b26807756021f0f1788e927074343

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. R. Narayan
2. W. Charman
3. S. Garg
4. Colin W. Pouton
5. Christopher J. H. Porter
6. S. Charman
7. H. Williams
8. R. Shanker

In Pharmaceutical Science

1. Christopher J. H. Porter
2. W. Charman
3. Natalie L. Trevaskis
4. S. Charman
5. H. Williams
6. R. Shanker
7. Colin W. Pouton
8. D. McClements

Citations in the corpus

• Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances (2018, background): “Myocet® Liposome Doxorubicin Breast cancer [16] Emend® Nanocrystals Aprepitant Antiemetic [17] Megace ES® Nanocrystals Megestrol acetate Anorexia [17] Tricor® Nanocrystals Fenofibrate In hypercholesterolemia [17]”
• Strategies to Address Low Drug Solubility in Discovery and Development (2013, background): “The principle, however, applies equally to solid particles in a liquid medium where a reduction in particle size below 1 mm increases solvation pressure, subsequently giving rise to an increase in solubility (Junghanns and Muller, 2008).”
• Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability (2014, background): “…advantages of enhancing the solubility and dissolution which helps in fast absorption and fast onset of action of the drug and moreover allows the formulation to be developed without the use of surfactants, which is sometimes advantageous in reducing the undesired effects of some excipients [21].”